• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » FDA Approval of VNS: The All-Too-Human Side of a Bureaucracy

FDA Approval of VNS: The All-Too-Human Side of a Bureaucracy

January 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

First they said yes to VNS, then no, then yes. And now they’re trying desperately to explain their final answer.

On June 15, 2004, the Neurological Devices Panel of the Medical Devices Advisory Committee voted by a 5-2 margin to recommend VNS for approval for TRD.

We encourage our readers to go to the transcript of this meeting, at http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4047t1.htm, in order to get a feel for how human a process an FDA advisory meeting is.

The Neurological Devices Panel is composed mainly of psychiatrists and neurologists, with a smattering of statisticians, consumers, and industry representatives. These 10 panelists heard testimony from a variety of people in support of VNS. These participants include those you’d expect -- Cyberonics employees and research psychiatrists they’ve sponsored -- but there were also several satisfied patients from VNS trials who volunteered to testify, the president of a Cyberonics-funded psychiatric consumer group, and a representative from our own APA.

While the basic science behind device approval involves dry statistics, this meeting was anything but dry. The patient testimony was particularly poignant and compelling:

“All I can say is that my life is full of genuine happiness and joy. I don't have to fake it anymore.… Last Saturday night I attended a small dinner party that 18 months ago I never would have gone to. I am also working on several different projects. This is the most productive I have been in many years” (testimony of Charles Donovan, III).

But one has to take some of this testimony with a grain of salt. Mr. Donovan’s trip and lodging were paid for by Cyberonics, and he has made something of a career out of VNS-boosterism, with his own website (www.vagusnervestimulator.com), a book (Out of the Black Hole: The Patient’s Guide to Vagus Nerve Stimulation and Depression), interviews with the major networks, and his own booth at the major psychiatric meetings.

Such personal testimonies were likely crucial for approval, because the statistics impressed few panel members, even those who voted in favor of approval. For example, Dr. Mary Jensen, a neuroradiologist, explained her yes vote by saying, “Although it would be nice to have randomized controlled data for the efficacy, I believe this is a difficult patient population.… And I think [VNS] should at least be available for this group of patients.”

This was the sentiment echoed by others: the evidence for efficacy is poor, but the pain of TRD is extreme, so let’s go ahead and approve it.

In August 2004, however, the FDA opted to overrule this panel’s vote (a very unusual occurrence), and rejected the application. In response, Cyberonics’ fiery CEO, Robert Cummins, went into high gear. In various conference calls and press releases, he insulted FDA’s "junior, ill-informed scientists" and suggested that the FDA would now be to blame for the suicides every month of “2,500 people” with treatment-resistant depression (see www.thestreet.com/comment/adamfeuerstein/10177974.html for TheStreet.com’s coverage of this issue). Cummins’ passion on this issue is notorious, and may be motivated by the fact that both his mother and grandfather committed suicide.

On Feb 3, 2005, the FDA, apparently swayed by Cummins’ arguments and by his submission of more long term data (all open label, however), again reversed itself, this time saying they would approve the device. Wall street analysts called this decision “stunning,” even more perplexing than the initial FDA rejection in the context of the panel’s approval.

At least this time, it looks like the FDA has made up its mind for good.

TCPR Verdict:
And thus waffled the FDA...
General Psychiatry
KEYWORDS antidepressants brain_devices
    www.thecarlatreport.com
    Issue Date: January 1, 2006
    SUBSCRIBE NOW
    Table Of Contents
    Vagus Nerve Stimulation: Is the Evidence Convincing?
    FDA Approval of VNS: The All-Too-Human Side of a Bureaucracy
    Choosing Antidepressants
    VNS: Some Practical Information
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.